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ABSTRACT
The cancer burden continues to grow with enormous physical, emotional, and financial pressure on 
individuals, families, communities, and health systems. Early detection and effective treatment are crucial. 
The analysis of epigenetic biomarkers is presented as an exceptional solution for early cancer diagnosis 
and personalised treatment design. These brand new biomarkers have initiated a diagnostic revolution 
because of their predictive capability and reversibility, opening the window for timely diagnostics and 
personalised medicine. In recent years, the potential of optical biosensors for epigenetic biomarker 
evaluation has been revealed. Nanotechnology is promoting the appearance of new advanced biosensors 
able to be integrated in complete lab-on-chip platforms. Lab-on-chip biosensors are offering simplified, 
cost-effective, and fast results to solve the current diagnostic problems. In this review, we present the 
advantages offered by the analysis of epigenetic routes in cancer diagnosis and the current advances in 
optical biosensors for cancer epigenetic analysis, showing how the new biosensor solutions manage to 
surpass the challenges encountered during the analysis of each epigenetic mechanism.
Keywords: Cancer diagnosis, biosensors, nanomedicine, biomarkers, biotechnology, epigenetics, gene 
regulation pathways.
EDITOR’S PICK
This issue’s Editor’s Pick is a relevant discussion paper from Lechuga et al. on the potential of  
simple, low-cost, and timely optical biosensors for the detection of epigenetic biomarkers in 
cancer diagnosis. The development of new methods for the detection and monitoring of cancer 
has been the subject of intense research over the last few years and the role of biosensors in  
the analysis of epigenetic biomarkers offers a promising solution.
Samantha Warne
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INTRODUCTION
Cancer is one of the leading life-threatening 
diseases across the world, with 200 different types 
of cancer accounting for >1,500 deaths per day.1 
The main constraints in cancer management can 
be found in two principal problems: late diagnosis 
and low efficiency of therapies. Despite the recent 
technological advancements, cancer diagnosis is 
still an unfinished issue for physicians, since many 
cancers remain asymptomatic until relatively 
late stages, leading to a poor survival rate.1 The 
continuous failure of many treatments against late-
diagnosed cancers is forcing scientists to establish 
new formulas for cancer prediction and staging. 
A better definition of the tumour origin and its 
stage of development will reduce the possibility of 
treatment defeat. Current conventional methods 
are inefficient for early stage cancer detection, as 
they are based on the evaluation of the phenotypic 
properties of the tumour.1 In addition, these 
techniques are invasive, expensive, and rely on time-
consuming procedures carried out in specialised 
laboratories. Regarding the applied therapies, most 
of them are not as precise and accurate as required, 
resulting in low success rates or devastating 
side-effects, which makes the identification of 
more specific drugs an indispensable requisite, 
and proper doses that best benefit each individual. 
There are several molecules that express 
prominent alterations in their expression during 
cancer, recognised as biomarkers and having high 
clinical significance. The presence, absence, or 
change in the level of these specific biomarkers 
in a cell, tissue, or biofluid often indicates cancer 
development.2,3 Cancer is a multistage disease 
of which onset and progression are associated 
with a complex variety of genetic or epigenetic 
alterations, resulting in tumourigenic transformation 
and progression.4 Epigenetics literally means ‘above’ 
or ‘on top of’ genetics. It refers to any heritable 
trait that is not derived from the DNA sequence. 
These inherited characteristics are transmitted 
to offspring in the form of subtle chemical 
modifications to DNA and DNA-associated proteins, 
and exert their effects by modulating the gene 
expression. Epigenetic mechanisms are implicated 
in several processes, playing important roles in 
cellular decision-making and providing the cells 
with a powerful capability to readily change 
their genomic expression in order to survive 
and reproduce successfully in ever-changing 
environments. For that reason, the field of 
epigenetics is considered a promising solution 
for cancer prediction and eradication. New 
discoveries in the epigenetic regulation of cells 
are gaining more and more attention in diagnosis. 
These epigenetic mechanisms have been shown 
to play important roles during cell development 
and equilibrium maintenance. Chatterjee and 
Zetters’2 study helped elucidate the shortcuts 
that cancer cells take by shifting these regulating 
routes for longer survival and proliferation over 
normal cells. Furthermore, several epigenetic 
changes occur prior to histopathological 
changes, constituting outstanding biomarkers 
for early cancer identification, diagnosis, and 
risk assessment.3 With a better knowledge of 
epigenetic mechanisms, one would be able to 
understand when, why, and how a tumour is 
produced. In addition, the specific reversion of 
these routes represents an excellent therapy 
solution in order to return the cancer cells to 
their normal state, without implying invasive 
chemotherapies and post-treatment side effects. 
Currently, new diagnostic devices are being 
developed in order to decipher and keep track 
of these epigenetic mechanisms.4 These tools 
use highly advanced technologies that allow a 
simpler and more cost-effective diagnosis. The 
ultimate goal is to use the devices outside the 
laboratory for the continuous monitoring of the 
patient before and after treatment. Such devices 
may allow the simultaneous detection of multiple 
biomarkers belonging to a previously defined cancer 
epigenetic profile. In this context, nanotechnology 
is playing a decisive role by offering ultrasensitive 
devices with powerful and highly improved 
performances as compared to the current 
diagnostic techniques.5 The combination of 
nanotechnology and epigenetics is advancing 
towards a new generation of cancer diagnostic 
tools, where the primary objective is to provide 
low-cost, simple, and ultra-detailed analyses of 
the patients’ clinical conditions in record time. 
This early diagnosis will define a newer and hopeful 
starting point for cancer treatment, helping 
design specific protocols and targets for therapies 
specifically tailored for each individual.
This manuscript reviews the benefits provided 
by the study of epigenetic mechanisms and their 
relationship with cancer. We also present some 
emergent, brand new nanobiosensor technologies, 
aiming to provide an advanced diagnostic tool 
by analysing the epigenetic mechanisms altered 
in cancer. The new nanosensors accomplished 
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the premises of user-friendly, reduced costs, 
and improved performance, priming them to spark 
a diagnostic revolution. 
THE CANCER EPIGENETIC SIGNATURE
Different epigenetic mechanisms control the 
gene expression at different levels, constituting a 
complex, highly structured gene regulatory 
network. One of the most relevant epigenetic 
processes is DNA methylation. It consists of the 
addition of methyl groups to cytosine nucleotides 
(5-methylcytosine [5-mC]) in the DNA sequence 
to impede transcription, aiding cells to modulate 
the expression of the implicated genes at their 
convenience.5 In the same way, the cell can 
reorganise its chromatin structure with another 
epigenetic mark, the acetylation/deacetylation of 
its histones, affecting the transcription process. 
This epigenetic regulation of the transcription 
process has a strong influence at the post- 
transcription level, as in the case of the regulation 
of alternative splicing of messenger RNA (mRNA), 
which gives the cell the capability to alternatively 
edit a pre-mRNA to produce proteins with 
different functions, increasing diversity.6 On the 
other hand, cells can regulate the gene expression 
through micro-RNA. These small, single-stranded, 
non-coding RNA typically contain 19–23 nucleotides 
and play important roles in modulating several 
biological functions through their interaction 
with mRNA.7 In this way, cells will either translate 
or not a specific gene via the regulation of 
epigenetic control.
All these mechanisms are interconnected and play 
important roles in every process of life, including 
cell differentiation, metabolism, cell cycle, and 
signal transduction. Therefore, it is not surprising 
that their alteration disturbs the fate of cells and 
the consequences can be devastating, resulting 
in the origin of grave diseases, one of the most 
predominant of which is cancer. In fact, aberrant 
DNA methylation has been linked to the silencing 
of tumour suppressor genes, leading to the cancer 
development.8 Most cancers are associated with a 
switch in the splicing pattern of specific isoforms, 
providing them with a highly proliferative capacity 
and survival properties.9 Likewise, an aberrant 
expression of specific micro-RNA sequences has 
been directly linked to the generation of tumours.10 
As a consequence, these epigenetic mechanisms 
are now being considered hallmarks of cancer. 
Current cancer biomarkers are based on 
overexpressed cancer proteins in blood; however, 
their number and clinical use are rather limited 
and require a large population of cancer patients 
with well-defined clinical staging and outcomes. 
Analysis of the epigenetic pathways may be 
more informative, specific, and accurate than the 
analysis of such protein biomarkers, by the 
determination of not only the cancer itself, 
but also the underlying mechanisms by which it 
is generated. Recent studies indicate that these 
regulation pathways participate in collaborative 
activities resulting in a common outcome.11 
Understanding the dynamics of these networks 
can shed light on the mechanisms responsible 
for the development of many types of cancer. 
On top of this, it will contribute to a more efficient 
management of cancer patients, providing an early 
diagnosis, determining precise tumour staging, 
and monitoring of treatment.
The revolutionary epigenetic inheritance has 
changed how we understand and deal with cancer. 
The dynamic nature and potential reversibility 
of the epigenetic mechanisms mean that they 
are appealing therapeutic targets in cancer 
treatment. Applying therapies focussed on reversion 
of the altered processes to their normal state 
would abate the cancer progression in a less 
invasive and more efficient manner than standard 
chemotherapies. Currently, various compounds 
that can rearrange DNA methylation and histone 
acetylation patterns are being examined in clinical 
settings in combination with other drugs.12,13 
Likewise, different approaches for mRNA and 
non-coding-RNA expression control are currently 
being assessed in order to potentially use them 
in more directed therapies.14-17 Therefore, a better 
knowledge of cell decision-making in cancer can 
be better exploited for the development and 
implementation of a more personalised medicine.
BIOSENSORS: 
THE DIAGNOSTIC SOLUTION
Advances in DNA/RNA detection techniques have 
recently hit the epigenetic field. Developments in 
real-time polymerase chain reaction (PCR) have 
allowed results to be obtained in a matter of a 
few minutes regarding the methylation status or 
mRNA isoform shift.18,19 DNA microarrays permit 
the interrogation of thousands of micro-RNA 
sequences simultaneously in one sample,20 while 
next-generation DNA sequencing technologies 
have expanded to genome-wide scale screening 
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and have achieved a resolution to single 
base precision.21 However, these methods suffer 
technological limitations, such as slow turnaround 
times,22 relatively large input volume,23 and biases 
arising from sample contamination and PCR-induced 
artifacts.24,25 They usually require the consumption 
of expensive reagents in every assay and need 
trained personnel for their manipulation due to 
the complexity of the analytical protocols. Besides, 
all cancers involve more than one epigenetic 
mechanism, making the simultaneous detection of 
multiple epigenetic biomarkers essential. 
Emerging trends in diagnostics have promoted the 
development of diagnostic tools with improved 
sensitivity and short operation times, such as 
biosensors. Biosensors can be designed to provide 
quantitative analytical information with elevated 
accuracy in a few minutes, using low sample volumes 
and minimum sample pretreatment. By definition, 
a biosensor is a self-contained analytical 
device that incorporates a biologically active 
material in intimate contact with an appropriate 
transduction element for the purpose of detecting, 
in a very selective way, the concentration 
or activity of chemical species in any type of 
sample (Figure 1).26 
Biosensors are threatening to radically alter our 
present concept of clinical analysis, beginning 
many years ago27 with the introduction of the 
glucose biosensor signifying a breakthrough in 
healthcare by the decentralisation and simplicity 
of analysis at home by one blood-drop.28 The 
principal aim of biosensors is to get away from the 
centralised laboratory and to provide analytical 
services closer to the patient: at the bedside, 
in the physician’s office, or by the patient at home. 
Nowadays, there are some commercial biosensors 
for several applications, such as detection of 
clinical biomarkers or pathogens and toxic 
metabolites for environmental/food contamination 
and bio-threats.29 Biosensor devices can show 
extremely low detection limits, which permits the 
detection of biomarkers at their physiological 
concentrations, assisting in the diagnosis of cancer 
at very early stages. In the last decades, a particular 
interest has been focussed on the development of 
novel, label-free optical biosensors able to generate 
a signal directly by the interaction of the analyte 
of interest with the recognition element, without 
requiring additional interactions with other probes 
carrying a label that provides the signal. In general, 
label-free methods offer potential advantages in 
terms of simplicity and velocity of the bioanalysis, 
which may not require washing steps or additional 
reagents. These biosensors enable the real-time 
monitoring of the biomolecular interaction, speeding 
up detection and giving access to the kinetic 
parameters of the recognition process.30 Moreover, 
with the advent of micro and nanotechnology, 
more sophisticated label-free, optical biosensors 
combine extremely high-quality performances and 
ultrasensitive limits of detection with the ability 
to miniaturise and integrate different functional 
components such as microfluidics, electronics, 
etc. in a single platform. These characteristics 
allow for the fabrication of smaller, cheaper, and 
easy-to-use biosensor devices that can accelerate 
the real implementation of lab-on-a-chip devices 
in clinical practice. 
Figure 1: Schematic diagram of a biosensor device. 
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Optical biosensors have shown exceptional 
capabilities for the detection of DNA/RNA 
sequences, at detection limits more than adequate 
for the physiological concentration of the target 
sequences in real samples.31 All optical biosensors 
developed so far for epigenetic biomarkers are 
characterised by the commitment to overcome 
the challenges encountered in their analysis 
(see Table 1 for a summary). 
For instance, the modification of the DNA 
sequence by methyl-groups has been of interest 
in many optical biosensor applications.32 Some 
methodologies carried out analysis of DNA 
methylation through bisulfite conversion, employing 
a surface plasmon resonance (SPR) biosensor. 
This type of biosensor uses a gold layer as both 
a surface to immobilise specific probes and 
a transducer of the signals produced by the 
refractive index changes at the surface.33 Bisulfite 
converts non-methylated cytosine nucleotides into 
uracil nucleotides, allowing the identification of 
different methylated or non-methylated sequences 
by different amplification processes, such as 
PCR34 or molecular inversion probe amplification.35 
However, bisulfite conversion does not differentiate 
between other epigenetic marks derived from 
enzymatic oxidisation of 5-mC, with important 
significance in the determination of the methylation 
status.36 Also, the possibility of bias introduced 
by errors in this pre-manipulation process 
has promoted the search for other alternatives. 
Specific recognition of methyl-sites (and derivatives) 
has been solved with specific antibodies37,38 
or proteins39 being able to quantify the number 
of cytosines without the necessity of sample 
manipulation. In this way, new microfluidic 
designs have been proposed in order to provide 
smaller and more easy-to-handle equipment for 
DNA methylation analyses.38 The microfluidics 
incorporate different pre-treatment processes on 
the same microchip as the methylation analysis, 
such as fragmentation by restriction enzyme to 
obtain the fragment of interest, mixture with a 
biotinylated bulge-inducer probe to improve the 
methyl-group accessibility, and heat denaturation 
and cool down for hybridisation. 
In the case of micro-RNA detection, due to their 
small size, short RNA regulators are difficult to 
amplify through conventional methods. In addition, 
they usually belong to a micro-RNA family with 
very similar sequences that can distort the analysis 
with false positive signals. The main objective 
towards micro-RNA detection relies on two 
premises: specificity and a high sensitivity to cover 
a wide range of concentrations. The ability to 
perform the experiments directly from an untreated 
biofluid without the need for purification steps, 
thereby risking sample input, is also important. 
Table 1: Challenges in the biosensing of epigenetic mechanisms and different biosensor approaches.
PCR: polymerase chain reaction; SPR: surface plasmon resonance.
Epigenetic 
pathway
Detection drawbacks in conventional methods Biosensor approaches
DNA 
methylation





Bisulfate conversion-based SPR biosensors34,35
Antibody-based methyl recognition SPR biosensor37,38
Methyl-binding protein-based SPR biosensor39
Micro-RNA Small fraction of total RNA (˜0.01%)
Difficult to amplify
Wide dynamic range: expression levels vary 
from a few copies to >50,000 copies per cell




Triplex-forming probe-based SPR biosensor43
Multiplexed immuno-amplification microring 
resonator-based biosensor44
Multiplex nanophotonic interferometer biosensor45
Alternative 
splicing
Target accessibility (long sequences 
≤1,000,000 nucleotides)




Multiplex nanophotonic interferometer biosensor48
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Some SPR biosensors have been developed for the 
analysis of micro-RNA. Šípová et al.40 demonstrated 
the detection of specific micro-RNA in mouse liver 
tissues. To achieve the required sensitivity levels 
without PCR-amplification steps, researchers 
used a signal enhancer based on a specific 
antibody.40 Other signal enhancers have also been 
proposed, such as nanoparticles41,42 or specially 
designed probes, which promote a better target 
capture.43 Another approach based on microring 
resonator biosensors has been proposed.44 The 
miniature size of the microrings offers the possibility 
of an array of biosensors (32 microring resonators 
within a 6×6 mm footprint) for multiplexed 
measurements, which is very encouraging for their 
use in routine clinics. On the other hand, our team 
has designed a nanotechnology-based optical 
biosensor with multiplexing capabilities that has 
been able to cover the total analytical range from 
attomolar to nanomolar concentrations, skipping 
any further enhancement.45 The biosensor consists 
of optical waveguides, the nanometre dimensions 
of which change the properties of the guided light, 
generating ultra-sensitive interferometric signals 
able to detect attomolar concentration of micro-
RNA directly in urine samples from bladder cancer 
patients. Its miniaturised size allows for multiplex 
arrays formats, incorporating 20 nanosensors within 
the same sensor chip (10 mm width, 31 mm length).
Few optical biosensors have been devised in order 
to use the alternative splicing regulation route 
for diagnostic purposes,6-8 probably due to the 
long RNA sequences and the similarity between 
mRNA isoforms that critically complicate the 
differentiation between the isoforms. Single 
mRNA-spliced variants have been identified and 
quantified in living cells by quantitative imaging.46 
This advance may enhance the understanding of 
pharmacogenomics, genetic diagnosis, and gene 
therapies. Another methodology incorporated a 
fragmentation process in order to adapt the length 
of the isoforms to the biosensor convenience 
and standardise the detection procedure.47 
The amplification-free methodology performed an 
accurate and efficient analysis of the alternative 
spliced isoforms from different genes and 
contexts in HeLa cells. In addition, the further 
implementation of the methodology in a multiplexed 
nanophotonic biosensor not only improved 
the sensitivity of the detection, but also would 
allow the simultaneous detection of an array of 
biomarkers with the same biosensor chip.48 
CHALLENGES IN 
EPIGENETIC BIOSENSING
Despite the significant advances and the 
promising perspectives of these new emerging 
diagnostic optical biosensors for identifying cancer 
epigenetics, they still face several challenges. 
Epigenetics is a relatively young discipline and, as 
such, still more fundamental knowledge is needed 
for its translation into diagnostics as an accurate 
mark of cancer. Due to the immense network 
of different epigenetic routes, it is strictly 
indispensable to establish accurate and well- 
defined epigenetic panels to be correlated with 
concrete cancer profiles. These panels cannot 
give rise to possible misleading diagnostics and 
should have sufficient consistence to offer a 
robust diagnosis. Once this accurate definition 
takes place, many clinical trials have to be done 
in order to establish standard patterns between 
different individuals and set up threshold 
concentration that confirms the presence and 
spreading of a tumourigenic process. For cancer 
stratification, different stage profiles need to be 
predefined in order to know the stage and level of 
progression of the cancer. 
On the other hand, the biosensor field is still far 
from meeting some of the key end-user needs. 
Most biosensor technologies should be focussed on 
matching or even improving their sensitivity levels 
to the conventional methodologies, without the 
need for sample premanipulation processes. 
Efforts are also focussed on the development 
of biosensors capable of multi-test detection 
and simultaneous monitoring. In terms of 
optical biosensor integration, new microfluidic 
approaches need to be addressed in order to 
overcome the specific requirements for each 
epigenetic mechanism and compartmentalisation 
for individualised analysis inside the same sensor 
platform. Also, the stability, reproducibility, and life 
cycle should be tested and guaranteed.
CONCLUSION
The benefits of optical biosensors for the routine 
analysis of epigenetic biomarkers is changing 
the concept of cancer diagnosis. The analysis of 
epigenetic regulation processes is a top requisite 
for the careful dissemination of tumour onset and 
the development of personalised treatments in 
order to reverse the affected mechanism in each 
cancer and patient. The possibility for rapid, 
 ONCOLOGY  •  October 2017  •  Creative Commons Attribution-Non Commercial 4.0 EMJ  EUROPEAN MEDICAL JOURNAL  ONCOLOGY  •  October 2017  •  Creative Commons Attribution-Non Commercial 4.0 EMJ  EUROPEAN MEDICAL JOURNAL 60 61
1. Jayanthi VSPKSA et al. Recent 
advances in biosensor development 
for the detection of cancer biomarkers. 
Biosens Bioelectron. 2017;91:15-23.
2. Chatterjee SK, Zetter BR. Cancer 
biomarkers: knowing the present and 
predicting the future. Futur Oncol. 2005; 
1(1):37-50.
3. Veenstra TD et al. Biomarkers: 
Mining the biofluid proteome. Mol Cell 
Proteomics. 2005;4(4):409-18.
4. del Sol A et al. Diseases as network 
perturbations. Curr Opin Biotechnol. 
2010;21(4):566-71.
5. Fuks F. DNA methylation and histone 
modifications: Teaming up to silence 
genes. Curr Opin Genet Dev. 2005;15(5): 
490-5.
6. Liu H et al. Alternative 
splicing regulation and cell lineage 
differentiation. Curr Stem Cell Res Ther. 
2012:7(6):400-6.
7. He L, Hannon GJ. MicroRNAs: Small 
RNAs with a big role in gene regulation. 
Nat Rev Genet. 2004;5(7):522-31.
8. Esteller M. Aberrant DNA methylation 
as a cancer-inducing mechanism. Annu 
Rev Pharmacol Toxicol. 2005;45:629-56.
9. Oltean S, Bates DO. Hallmarks of 
alternative splicing in cancer. Oncogene. 
2013;33:5311-8. 
10. Jansson MD, Lund AH. MicroRNA and 
cancer. Mol Oncol. 2012;6(6):590-610.
11. Murr R. Interplay between different 
epigenetic modifications and 
mechanisms. Adv Genet. 2010;70:101-41.
12. Christman JK. 5-Azacytidine and 
5-aza-2’-deoxycytidine as inhibitors of 
DNA methylation: Mechanistic studies 
and their implications for cancer therapy. 
Oncogene. 2002;21(35):5483-95.
13. Zhou L et al. Zebularine: A novel 
DNA methylation inhibitor that 
forms a covalent complex with DNA 
methyltransferases. J Mol Biol. 2002; 
321(4):591-9.
14. Spitali P, Aartsma-Rus A. Splice 
modulating therapies for human disease. 
Cell. 2012;148(6):1085-8.
15. Ling H et al. MicroRNAs and other 
non-coding RNAs as targets for 
anticancer drug development. Nat Rev 
Drug Discov. 2013;12(11):847-65.
16. Esau CC, Monia BP. Therapeutic 
potential for microRNAs. Adv Drug Deliv 
Rev. 2007;59(2-3):101-14.
17. Bader AG, Lammers P. The therapeutic 
potential of microRNAs. Innov Pharm 
Technol. 2012;52-5.
18. Watanabe K et al. Development 
of a real-time PCR-based method for 
analyzing semen-specific unmethylated 
DNA regions and methylation status in 
aged body fluid stains. J. Forensic Sci. 
2016;61(Suppl 1):S208-12.
19. Pilbrow AP et al. Cardiac CRFR1 
expression is elevated in human heart 
failure and modulated by genetic variation 
and alternative splicing. Endocrinology. 
2016;157(12):4865-74.
20. Konishi et al. “Microarray Technology 
and Its Applications for Detecting Plasma 
microRNA Biomarkers in Digestive Tract 
Cancers”, Li PC et al. (eds.), Microarray 
Technology: Methods and Applications 
(2016), New York: Humana Press, pp. 
99-109. 
21. Shendure J, Ji H. Next-generation 
DNA sequencing. Nat Biotechnol. 2008; 
26(10):1135-45.
22. Thierry AR et al. Clinical validation 
of the detection of KRAS and BRAF 
mutations from circulating tumor DNA. 
Nat Med. 2014;20(4):430-5.
23. Mauger F et al. Comprehensive 
evaluation of methods to isolate, 
quantify, and characterize circulating 
cell-free DNA from small volumes of 
plasa. Anal Bioanal Chem. 2015;407(22): 
6873-8.
24. Schwarzenbach H et al. Cell-free 
nucleic acids as biomarkers in cancer 
patients. Nat Rev Cancer. 2011;11(6): 
426-37.
25. Spoto G, Corradini R (eds.), Detection 
of Non-Amplified Genomic DNA(2012). 
New York: Springer.
26. Lakshmi KR et al. Oral fluid-based 
biosensors: A novel method for rapid 
and noninvasive diagnosis. Indian J Dent 
Sci. 2017;9(1):60-6.
27. Owen VM, Turner APF. Biosensors: 
a revolution in clinical analysis? 
Endeavour. 1987;11(2):100-4.
28. Yoo EH, Lee SY. Glucose biosensors: 
An overview of use in clinical practice. 
Sensors (Basel). 2010;10(5):4558-76.
29. Bahadır EB, Sezgintürk MK. 
Applications of commercial biosensors 
in clinical, food, environmental, and 
biothreat/biowarfare analyses. Anal 
Biochem. 2015;478:107-20.
30. Graybill RM, Bailey RC. Emerging 
biosensing approaches for microRNA 
analysis. Anal Chem. 2016;88(1):431-50.
31. Carrascosa LG et al. Prospects of 
optical biosensors for emerging label-
free RNA analysis. TrAC - Trends in 
Analytical Chemistry. 2016;80:177-89.
32. Nazmul Islam M et al. 
Optical biosensing strategies for 
DNA methylation analysis. Biosens 
Bioelectron. 2017;92:668-78.
33. Homola J et al. “Surface plasmon 
resonance biosensors”, Ligler FS, Taitt 
CR (eds.), Optical Biosensors: Today 
and Tomorrow (2008) 2nd edition, 
Amsterdam: Elsevier, pp.185-242.
34. Carrascosa LG et al. Molecular 
inversion probe-based SPR biosensing 
for specific, label-free and real-time 
detection of regional DNA methylation. 
Chem Commun (Camb). 2014;50(27): 
3585-8.
35. Shiddiky MJ et al. Methylsorb: A 
simple method for quantifying DNA 
methylation using DNA-gold affinity 
interactions. Anal Chem. 2014;86(20): 
17-20.
36. Chowdhury B et al. 
Quantification of 5-methylcytosine, 
5-hydroxymethylcytosine and 
5-carboxylcytosine from the blood of 
cancer patients by an enzyme-based 
immunoassay. Anal Chim Acta. 2014; 
852:212-7.
REFERENCES
very sensitive, and multiplex detection of different 
epigenetic mechanisms involved in tumour 
progression makes these devices an outstanding 
solution for cancer management. Several biosensor 
approaches have already been shown to fulfil 
the needs and overcome the challenges that 
conventional tools for epigenetic analysis are 
seeking nowadays. Further investigations are 
devoted to developing more robust, sophisticated, 
and easy-to-use devices. The combination 
of nanotechnology with epigenetic analysis 
constitutes a breakthrough in cancer theranostics, 
i.e. the use of one particular molecular diagnostic 
to guide therapeutic decisions, since it offers the 
possibility of not only providing a more in-depth 
vision of the tumourigenic process, but also paves 
the way for a more directed and effective route 
to design therapies aiming at eradicating cancer 
and increasing patient quality of life. 
 ONCOLOGY  •  October 2017  •  Creative Commons Attribution-Non Commercial 4.0 EMJ  EUROPEAN MEDICAL JOURNAL  ONCOLOGY  •  October 2017  •  Creative Commons Attribution-Non Commercial 4.0 EMJ  EUROPEAN MEDICAL JOURNAL 60 61
37. Kurita R, Niwa O. DNA methylation 
analysis triggered by bulge specific 
immuno-recognition. Anal Chem. 2012; 
84(17):7533-8.
38. Kurita R et al. On-chip sequence-
specific immunochemical epigenomic 
analysis utilizing outward-turned 
cytosine in a DNA bulge with handheld 
surface plasmon resonance equipment. 
Anal Chem. 2015;87(22):11581-6.
39. Pan S et al. Double recognition 
of oligonucleotide and protein in the 
detection of DNA methylation with 
surface plasmon resonance biosensors. 
Biosens Bioelectron. 2010:26(2):850-3.
40. Šípová H et al. Surface plasmon 
resonance biosensor for rapid label-free 
detection of microribonucleic acid at 
subfemtomole level. Anal Chem. 2010; 
82(24):10110-5.
41. Vaisocherová H et al. Rapid 
and sensitive detection of multiple 
microRNAs in cell lysate by low-fouling 
surface plasmon resonance biosensor. 
Biosens Bioelectron. 2015;70:226-31.
42. Wang Q et al. Graphene oxide-
gold nanoparticles hybrids-based 
surface plasmon resonance for 
sensitive detection of microRNA. Biosens 
Bioelectron. 2016;77:1001-7.
43. Aviñó A et al. Sensitive and 
label-free detection of miRNA-145 by 
triplex formation. Anal Bioanal. Chem. 
2016;408(3):885-93.
44. Qavi AJ et al. Anti-DNA:RNA 
antibodies and silicon photonic microring 
resonators: Increased sensitivity for 
multiplexed microRNA detection. Anal 
Chem. 2011;83(15):5949-56.
45. Huertas CS et al. Direct and label-
free quantification of micro-RNA-181a at 
attomolar level in complex media using a 
nanophotonic biosensor. ACS Sens. 2016; 
1(6):748-56. 
46. Lee K et al. Quantitative imaging of 
single mRNA splice variants in living cells. 
Nat Nanotechnol. 2014;9(6);474-80.
47. Huertas CS et al. Quantitative 
evaluation of alternatively spliced 
mRNA isoforms by label-free real-time 
plasmonic sensing. Biosens Bioelectron. 
2016;78:118-25.
48. Huertas CS et al. Analysis of 
alternative splicing events for 
cancer diagnosis using a multiplexing 
nanophotonic biosensor. Sci Rep. 2017; 
7:41368.
If you would like reprints of any article, contact: +44 (0) 1245 334450.
